Compare Entegris Inc (ENTG) vs Philip Morris International Inc. (PM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Entegris Inc vs Philip Morris International Inc. — how do they compare? Entegris Inc trades at $163.19 (market cap $24.78B), while Philip Morris International Inc. trades at $200.42 (market cap $312.50B). The key difference: Philip Morris International Inc. is far larger — about 12.6× Entegris Inc's market cap, and Philip Morris International Inc. pays the higher dividend (3.19%). Which is the better fit depends on your goals — on Pluang, investors hold Entegris Inc for 41 Days and Philip Morris International Inc. for 85 Days on average.
| ENTG | PM | |
|---|---|---|
Market Cap | $24.78B | $312.50B |
Volume | 2,648,320 | 5,517,172 |
Sector | Technology | Consumer Staples |
52-Week High | $184.00 | $200.50 |
52-Week Low | $68.80 | $144.33 |
Typical Hold Time | 41 Days | 85 Days |
Enterprise Value | $27.99B | $355.62B |
Dividend Yield | 0.25% | 3.19% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ENTG trades at $166.32, down 0.34% on the day, with a bullish technical signal and strong institutional backing. The stock has consistently beaten earnings estimates in recent quarters, with Q2 2026 EPS of $0.93 surpassing the $0.822 forecast. Revenue remains stable around $3.2B, while profitability metrics show a net income margin of 9.18%. Recent news highlights robust AI-driven semiconductor demand and successful patent defenses.
The outlook is positive, supported by analyst consensus with a $182.43 price target and 70% buy ratings. Key opportunities include exposure to growing semiconductor complexity and AI investments. Risks involve high valuation multiples, such as a P/E of 81.1, and sensitivity to semiconductor industry cycles.
Philip Morris International (PM) trades at $192.69, up 1.2% today, with a bullish technical signal and strong analyst support. Recent Q2 2026 EPS beat expectations at $2.20 vs. $2.05, and revenue growth accelerated to $40.65B in 2025. The company's smoke-free products now drive 42% of revenue, with ZYN and IQOS expansions fueling optimism. Cash flow remains robust, with 2026 operating cash flow projected at $14.3B, supporting dividend growth.
Outlook is positive given earnings momentum and smoke-free transition, but high debt ($42.17B long-term) and regulatory risks persist. The consensus price target of $212.17 implies ~10% upside, though valuation multiples are elevated versus peers. Key risks include FX volatility and slower adoption of next-gen products.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Entegris Inc
Entegris Inc is a supplier of advanced materials and process solutions for the semiconductor and other high-technology industries. The company's reportable segments include Specialty Chemicals & Engineered Materials (SCEM), Microcontamination Control (MC), and Advanced Materials Handling (AMH). The SCEM segment provides high-performance & high-purity process chemistries, gases, & materials, and safe & efficient delivery systems. The Microcontamination Control (MC) segment includes solutions to purify critical liquid chemistries and process gases used in semiconductor manufacturing processes and other high-technology industries. Its geographical segments are Taiwan, North America, South Korea, Japan, China, Europe, and Southeast Asia.
Read more on ENTG →About Philip Morris International Inc.
Philip Morris International is an international tobacco company with a product portfolio primarily consisting of cigarettes and reduced-risk products, including heat-not-burn, vapor and oral nicotine products, which are sold in markets outside the United States. The company diversified away from nicotine products with the acquisition of Vectura, a provider of innovative inhaled drug delivery solutions, in 2021.
Read more on PM →
